Loading clinical trials...

Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol | Clinical Trials | Clareo Health

TERMINATEDPHASE3

Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

Open Label Study of the Effect of Daily Treatment With MPC-7869 in Subjects With Dementia of the Alzheimer's Type

NCT00380276•Myrexis Inc.

View on ClinicalTrials.gov

Summary

Open-label treatment with MPC-7869 for participants in a previous randomized study.

Eligibility

Age

55 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participation in a previous MPC-7869 randomized protocol
•Have had a diagnosis of probable Alzheimer's disease.
•Men or women ages 55 years or greater and living in the community at the time of enrollment (i.e., not living in a rest home or nursing care facility).
•Signed the subject Informed Consent Form and is willing and able to participate for the duration of the study.
•Female subjects must be surgically sterile or postmenopausal for \> 1 year.
•Subjects must have a reliable caregiver who can read, understand and speak English or Spanish.

Exclusion Criteria

•History or evidence of, active malignancy, except for basal cell carcinoma or squamous cell carcinoma of the skin, within the 24 months prior to entry. Men with prostate cancer may be enrolled at the discretion of the sponsor.
•Chronic or acute renal, hepatic or metabolic disorder.
•Use of any investigational therapy within 30 days, or 5 half-lives, whichever is longer, and/or use of AD immunotherapy prior to screening.

Locations (90)

Alabaster, Alabama, United States

Huntsville, Alabama, United States

Phoenix, Arizona, United States

Sun City, Arizona, United States

Tucson, Arizona, United States

Costa Mesa, California, United States

Irvine, California, United States

Lafayette, California, United States

Laguna Hills, California, United States

Long Beach, California, United States

Key Dates

Start Date

September 1, 2006

Completion Date

December 1, 2008

Last Updated

August 5, 2008

Enrollment

1,000

ESTIMATED participants

Conditions

Alzheimer's Disease

Interventions

MPC-7869

DRUG

ACP-204 in Adults With Alzheimer's Disease Psychosis

NCT06159673

Alzheimer's Disease Psychosis

View study

RECRUITING

Lombard Cohort of Brain Health Services

NCT07457138

Subjective Cognitive Decline (SCD)Functional Cognitive Disorder+2 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 5, 2008Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Open-Label Treatment With MPC-7869 for Patients With Alzheimer's Who Previously Participated in an MPC-7869 Protocol

Inclusion Criteria

Exclusion Criteria

ACP-204 in Adults With Alzheimer's Disease Psychosis

Lombard Cohort of Brain Health Services

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia